A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 25 Aug 2017 Planned End Date changed from 1 Oct 2017 to 31 Jan 2018.
- 25 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 31 Jan 2018.
- 04 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.